Hims & Hers Health (HIMS) Stock Up 7% Premarket Thursday, On Track for Best Week Ever

TLDR

• HIMS stock is up 7% in premarket Thursday, extending a 10% gain from Wednesday and putting it on track for a fourth straight day of gains
• The stock has rallied 64% this week — its best weekly performance on record
• The surge was sparked by a partnership deal with Novo Nordisk, allowing HIMS to sell FDA-approved Ozempic and Wegovy on its platform
• Barclays raised its price target from $25 to $29 with an “overweight” rating; Bank of America upgraded from “underperform” to “neutral” with a target of $23
• Q4 EPS came in at $0.08, beating the $0.02 estimate, though revenue of $617.8M slightly missed the $619.5M consensus

Hims & Hers Health (HIMS) had a week it won’t forget. The stock is up roughly 7% in premarket trading on Thursday, following a 10% jump on Wednesday. That makes four straight sessions of gains.

Hims & Hers Health, Inc., HIMS

Through Wednesday’s close, HIMS has surged 64% this week. That’s its best weekly performance on record.

The rally started Monday when news broke that Novo Nordisk plans to distribute its weight-loss drugs through the Hims & Hers platform. The deal clears a legal overhang that had been hanging over the stock.

Under the agreement, Hims & Hers can now sell FDA-approved Ozempic and Wegovy directly to customers through its digital health platform. Analysts have called this a direct revenue and margin driver.

HIMS stock traded at $26.17 during midday Wednesday, up $2.70 on the day, with volume hitting 51.6 million — well above its average of 33.3 million.

Analyst Upgrades Roll In

The Novo Nordisk deal triggered a wave of analyst moves. Barclays raised its price target from $25 to $29, keeping an “overweight” rating. That implies about 10.8% upside from current levels.

Bank of America upgraded HIMS from “underperform” to “neutral” and lifted its target from $12.50 to $23. Deutsche Bank raised its target from $25 to $28, maintaining a “hold” rating.

The overall consensus from MarketBeat sits at “Hold” with a price target of $30.75. Three analysts rate it a Buy, thirteen say Hold, and one has a Sell.

The stock also saw unusually large options activity, with around 322,000 call contracts traded — a sign of strong bullish positioning that can amplify upside moves.

Q4 Earnings and Buyback

HIMS reported Q4 earnings on February 23. EPS came in at $0.08, well ahead of the $0.02 analyst estimate. Revenue was $617.8 million, just shy of the $619.5 million consensus.

Revenue was still up 28.4% year-over-year. The company posted a return on equity of 22.48% and a net margin of 5.47%.

The board also approved a $250 million stock buyback plan, covering about 3% of outstanding stock. Buyback authorizations typically signal that management believes the stock is undervalued.

Looking ahead, analysts expect full-year EPS of $0.29 for the current year.

The stock’s 52-week range is $13.74 to $70.43. At Wednesday’s close, it sits well above its 50-day moving average of $24.31 but still below its 200-day average of $37.75.

Despite the week’s gains, short interest remains a watch item. Analysts have flagged squeeze dynamics as a source of volatility — gains driven by short covering can reverse quickly once speculative pressure fades.

Institutional investors currently own 63.52% of HIMS stock. Insiders hold 17.71%, though insiders sold 80,463 shares in the last quarter.

The post Hims & Hers Health (HIMS) Stock Up 7% Premarket Thursday, On Track for Best Week Ever appeared first on CoinCentral.